Atika Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Atika Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,200	Closed	-$2.61M	–	83
2026 Q1	$2.61M	Buy	+35,200	New	+$2.55M	0.33%	58
2024 Q1	–	Sell	-9,000	Closed	-$306K	–	98
2023 Q4	$363K	Buy	+9,000	New	+$270K	0.05%	76
2023 Q2	–	Sell	-90,000	Closed	-$1.49M	–	86
2023 Q1	$1.49M	Buy	+90,000	New	+$1.05M	0.22%	73
2021 Q4	–	Sell	-73,500	Closed	-$3.45M	–	92
2021 Q3	$3.45M	Buy	73,500 +1,100	+2%	+$59K	0.21%	99
2021 Q2	$4.41M	Sell	72,400 -5,000	-6%	-$286K	0.35%	81
2021 Q1	$4.77M	Buy	77,400 +6,600	+9%	+$432K	0.41%	77
2020 Q4	$5.04M	Buy	70,800 +8,300	+13%	+$400K	0.39%	85
2020 Q3	$2.35M	Sell	62,500 -42,300	-40%	-$1.33M	0.19%	97
2020 Q2	$3.42M	Sell	104,800 -4,700	-4%	-$143K	0.44%	75
2020 Q1	$3.18M	Buy	109,500 +81,200	+287%	+$2.52M	0.61%	49
2019 Q4	$991K	Buy	+28,300	New	+$785K	0.19%	73

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Atika Capital Management's BBIO Position: Q2 2026 in Review

Atika Capital Management sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 35,200 shares — an estimated $2.61M sold.

Atika Capital Management first reported a position in BBIO in Q4 2019 and held it in 11 quarters. The position peaked at $5.04M in Q4 2020. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Atika Capital Management reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
Atika Capital Management sold 35,200 BridgeBio Pharma shares in Q2 2026, an estimated $2.61M.
Atika Capital Management first reported a position in BridgeBio Pharma in Q4 2019 and held it in 11 quarters.
Atika Capital Management's BridgeBio Pharma position peaked at $5.04M in Q4 2020.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Atika Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.